A new study is offering a surprising potential avenue for treating addiction: medications initially developed for type 2 diabetes. Researchers have found that GLP-1 receptor agonists – a class of drugs that includes semaglutide and tirzepatide – are associated with a reduced risk of developing substance use disorders and a decrease in harm for those already struggling with addiction. The findings, published in The BMJ, suggest these medications may target a common biological pathway underlying various forms of addiction, offering a potentially unifying approach to treatment.
The implications are significant, given the ongoing opioid crisis and the widespread challenges of addiction to substances like alcohol, cannabis, and nicotine. Current addiction treatments often focus on specific substances, requiring a tailored approach for each individual’s struggle. This research hints at a broader solution, one that could address the underlying cravings that drive addiction across the board. The study examined data from a large population, offering a level of insight not previously available.
GLP-1 medications have gained prominence in recent years, initially as a treatment for type 2 diabetes. More recently, they’ve become widely known for their effectiveness in promoting weight loss. Patients taking these drugs have frequently reported a diminished interest in highly palatable foods, a phenomenon often described as a quieting of “food noise.” Now, it appears this effect may extend to addictive substances as well.
A Broad Look at Addiction Risk
The research team, led by Ziyad Al-Aly, a clinical epidemiologist at Washington University School of Medicine in St. Louis and Chief of the Research and Development Service at the VA Saint Louis Health Care System, analyzed the electronic health records of over 606,000 US veterans with type 2 diabetes. The study participants were divided into two groups: those without a pre-existing substance use disorder and those who already had one. Researchers then tracked outcomes over up to three years, comparing those taking GLP-1 receptor agonists to those taking SGLT2 inhibitors, another class of diabetes medication.
The analysis revealed a 14% reduced risk of developing any substance use disorder among those taking GLP-1s compared to the control group. Specifically, the risk of developing an alcohol use disorder decreased by 18%, cannabis by 14%, cocaine and nicotine by 20%, and opioid use disorder by 25%. This translated to approximately seven fewer new substance use disorder diagnoses per 1,000 GLP-1 users, according to the study published in The BMJ.
For veterans already battling addiction, GLP-1s were linked to fewer serious consequences. After three years, researchers observed a 30% reduction in emergency department visits related to substance use, a 25% reduction in hospitalizations, a 40% reduction in overdose events, and a striking 50% reduction in drug-related deaths. This amounted to 12 fewer serious harm events per 1,000 GLP-1 users.
Targeting the Root of Craving
“In addiction medicine, a lot of treatments target just one thing,” explained Al-Aly. “A nicotine patch helps with smoking, but not alcohol. There is no medication that works across addictive substances, let alone all of them.” He believes the key lies in the drugs’ ability to address the underlying craving itself. “The revelation about GLP-1 medication is that it really works against all major substances, and it works uniformly, not because it acts against alcohol or opioids or nicotine specifically, but because it is likely acting against the craving itself. It blunts that craving that pulls people toward whatever they’re addicted to.”
The researchers hypothesize that GLP-1 receptors in the brain, particularly in regions involved in reward processing, play a crucial role. By modulating these receptors, the medications may reduce the intensity of cravings, making it easier for individuals to resist addictive behaviors. This concept builds on anecdotal reports from patients who found it easier to quit smoking or drinking after starting GLP-1s for diabetes or weight management.
Beyond Diabetes and Weight Loss: A New Potential Use?
While the study focused on veterans with type 2 diabetes, the findings raise the possibility of using GLP-1 medications as a direct treatment for addiction in a broader population. Al-Aly emphasized the potential for a “dual benefit” for individuals with both chronic conditions like diabetes or obesity and a substance use disorder. “One medication can treat both conditions at once,” he said.
However, Al-Aly cautioned that these findings are observational and do not prove causation. Rigorous clinical trials are needed to confirm these results and determine the optimal dosage and duration of treatment. He and his team are advocating for such trials, including studies specifically designed to measure the impact of GLP-1s on overdose and drug-related mortality. The National Institute on Drug Abuse (NIDA) offers resources and information on addiction research and treatment options on their website.
The potential impact is substantial. Millions of Americans are already taking GLP-1 medications, and their use is projected to continue growing. If these medications can indeed reduce the risk of addiction and its devastating consequences, it could represent a significant step forward in public health. The next step will be to see if these promising findings translate into effective, targeted treatments for those struggling with addiction.
This research was funded by the United States Department of Veterans Affairs. The funders had no role in the study’s design, conduct, data analysis, or manuscript preparation.
Do you have personal experience with GLP-1 medications or addiction treatment? Share your thoughts in the comments below.
